---
schema_version: "secwatch.filing_event.v1"
accession: "0001185185-26-002922"
form_type: "8-K"
ticker: "IGC"
cik: "0001326205"
company_name: "IGC Pharma, Inc."
filed_at: "2026-07-13T22:11:32+00:00"
generated_at: "2026-07-14T10:05:47.837752+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IGC Pharma updates investor presentation: Phase 2 CALMA trial >80% enrolled, interim data show agitation reduction

## Summary
- Phase 2 CALMA trial for IGC-AD1 in agitation in Alzheimer's: >80% of 146 target participants completed dosing.
- Blinded pooled data (n=107) show LS mean CMAI change of -13.6 at week 2 and -14.9 at week 6 from baseline.
- Interim analysis (n=26) showed IGC-AD1 numerically earlier and larger CMAI reduction vs published brexpiprazole data.
- Sleep disturbance reduced 71% at week 2 (p=0.012) and 78% at EOT (p=0.02) in interim analysis.
- Current market cap ~$30M; presentation outlines potential valuation inflection to $350M-$750M post positive Phase 2.

## SEC filing metadata
- accession: 0001185185-26-002922
- form_type: 8-K
- ticker: IGC
- cik: 0001326205
- company_name: IGC Pharma, Inc.
- filed_at: 2026-07-13T22:11:32+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326205/000118518526002922/0001185185-26-002922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326205/000118518526002922/igc8k071326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001185185-26-002922
- JSON: https://secwatch.observer/filing/0001185185-26-002922.json
- Plain text: https://secwatch.observer/filing/0001185185-26-002922.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.